Business Wire

OSAKA-BUSINESS-DEV-AGCY

15.12.2022 06:01:35 CET | Business Wire | Press release

Share
OBDA-Aiming to create a unicorn company from Kansai that can compete globally! Announcing the Joint Branding of ”Kansai Startup Mashups” From the Three Capitals of Osaka, Kyoto, and Kobe (Hyogo)

The Osaka Business Development Agency, in cooperation with the Keihanshin Startup Ecosystem Consortium and JETRO Osaka, has jointly launched the brand, “Kansai Startup Mashups” to support startups from the Kansai region that are taking on global challenges. From this release and on, we will use "Kansai Startup Mashups" as a branding tool to promote various initiatives for startups in the Kansai region to the global market.
The first event will be held on January 25, 2023, and the call for participants begins today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005391/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kansai Startup Mashups in Kobe, 25 / Jan / 2023. (Graphic: Business Wire)

Osaka, Kyoto, and Kobe offer an environment conducive to startups, with a concentration of bio- and healthcare-related companies, Monozukuri (manufacturing), ICT-related companies, as well as universities and research institutes.
Due to its strength environment, the "Osaka-Kyoto-Kobe(Hyogo) Consortium" was selected in 2020 as a global hub city in the Japanese government's strategy to become a world-class start-up hub, and universities, companies, and local governments are working to form an ecosystem of collaboration.

And now, with the aim to further accelerate these efforts, Osaka, Kyoto, and Kobe have jointly launched "Kansai Startup Mashups" as a unified brand for support.
The newly launched "Kansai Startup Mashups" aims to create a world-class startup ecosystem in anticipation of the 2025 Kansai Expo and the post-Kansai Expo, and to create a framework that will lead to the birth of unicorn companies from the Kansai region and the creation and support of startups that will grow to become major players.

In this initiative, the three capitals of Osaka, Kyoto, and Kobe will collaborate to link the circle of cooperation and support among universities, businesses, and government, and to disseminate Kansai startups both domestically and internationally, creating new synergies through the exchange of cutting-edge technology and domestic and international wisdom.
As part of this effort, toward the end of the fiscal year, we will be holding three events under a unified brand; ANCHOR KOBE on Wednesday, January 25, 2023 and engawa KYOTO on February 7, 2023.
On March 2, 2023, a large-scale event will be held at QUINTBRIDGE (Osaka) to unify and communicate the potential of Kyoto, Osaka, and Kobe to become the world's first to realize a future society on the occasion of the Osaka-Kansai Expo.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005391/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer11.8.2026 14:30:00 CEST | Press release

Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business OfficerAppointments deepen vaccine development expertise and enhance global commercial and strategic leadership ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisition by Merck; and Bill Warren, former Global Head of Antigen Design at Sanofi Vaccines, as independent members of ILiAD’s Board of Directors. The Company also announced the appointment of Antony Blanc, former VP, Head of Global Marketing and Global Strategic Pricing at GSK Vaccines, as Chief Business Officer. “Our recently appointed colleagues bring an extraordinary depth of experience in vaccine development, global commercialization, and strate

TEC reduces pressure on support teams with proactive outage communications powered by Adtran and GOCare11.8.2026 14:15:00 CEST | Press release

News summary: Fiber broadband providers need faster, more transparent ways to manage outages and reduce support surges TEC is now using GOCare OutageIQ integrated with Adtran’s outage notification API and Mosaic One to automate subscriber messaging Open APIs turn network insight into actionable workflows, improving responsiveness and operational efficiency Adtran and GOCare today announced that Telephone Electronics Corporation (TEC) has improved outage responses and reduced inbound support tickets using GOCare’s OutageIQ solution integrated with Adtran’s outage notification API and Mosaic One. Serving communities across Mississippi, Alabama and Tennessee, TEC delivers fiber broadband services built on a foundation of community investment and reliable service. By combining proactive notifications with real-time network insights, the service provider can now inform customers as issues are detected while equipping support teams with immediate context. This transparency helps build subscr

Kinaxis-Sponsored Study Identifies Supply Chain AI Accountability Gap Amidst Rapid Adoption Expectations11.8.2026 14:07:00 CEST | Press release

Trust, measurable outcomes, and governance lag, even as 41% expect autonomous-at-scale operations within two years Kinaxis® (TSX:KXS), a global leader in supply chain orchestration, today announced the findings of new independent research from IDC. The IDC InfoBrief, sponsored by Kinaxis, “Making Supply Chain AI Accountable,” reveals a growing chasm between organizations’ aggressive ambitions for autonomous AI adoption and their readiness to hold these advanced systems - which we believe underscores the need for a disciplined approach to AI investment and deployment to prevent costly failures and deliver measurable business value. What This Means for Supply Chain Leaders The IDC InfoBrief, which surveyed more than 2,000 supply chain leaders across nine global markets, found that while AI adoption is nearly universal - only 2% of respondents report no AI-enabled capabilities, and just 12% consider themselves AI leaders. Over half (52%) cite trust in AI-driven decisions as a top barrier

One in Four Executives Say AI Errors Have Reached External Audiences or Boards, According to New Research From Workiva11.8.2026 14:00:00 CEST | Press release

Although 84% of executives are at least somewhat confident in AI output without human review, only 11% believe their data quality is sufficient for AI use Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today released findings from its 2026 Midyear Executive Benchmark Survey. Although 84% of surveyed executives say they are at least somewhat confident in the accuracy of AI output without human review, one in four (26%) say internal audits have detected AI errors that reached external audiences or board members. This data suggests there is a disconnect between what executives believe and what evidence shows. As AI reshapes the enterprise at unprecedented speed, a new risk is emerging: transformation could be outpacing the instincts of the leaders tasked with overseeing it. "Confidence in AI without control over data quality is a liability, not a strategy. CFOs need platforms that connect AI to trusted, auditable data so every output

Altasciences Continues to Expand North American Bioanalytical Footprint11.8.2026 14:00:00 CEST | Press release

Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye